Home › Metastatic Cancer › NCT06630845
Comparison of Whole Body DWI to FDG PET
Recruiting
Comparison of Whole Body DWI to FDG PET Using PET/MRI
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Age ≥ 18 years. 2. Non FDG PET imaging study scheduled to be performed within 60 days (before or after) of the research PET/MRI. 3. Ability to understand a written informed consent document, and the willingness to sign it. 4. Diagnosis of metastatic cancer. Exclusion Criteria: 1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation. 2. Individuals with contraindications to MRI. This will be determined through review of the UCSF MRI screening form by qualified site personnel
About the study
This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.
What is being tested
- Fluorodeoxyglucose F18 (drug)
- Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI) (procedure)
- Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI) (procedure)
- General Electric (GE) SIGNA PET/MR (device)
Sponsor: University of California, San Francisco · Participants: 30 · Started: Feb 6, 2025
Contact the study team
- Brad Kline · Phone: 877-827-3222
Official record on ClinicalTrials.gov — NCT06630845
Locations in the U.S.
| California | University of California, San Francisco, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.